JP2021529196A - 疼痛の治療におけるマンヌロン二酸組成物の使用 - Google Patents

疼痛の治療におけるマンヌロン二酸組成物の使用 Download PDF

Info

Publication number
JP2021529196A
JP2021529196A JP2020572817A JP2020572817A JP2021529196A JP 2021529196 A JP2021529196 A JP 2021529196A JP 2020572817 A JP2020572817 A JP 2020572817A JP 2020572817 A JP2020572817 A JP 2020572817A JP 2021529196 A JP2021529196 A JP 2021529196A
Authority
JP
Japan
Prior art keywords
pain
total weight
composition
acid
mannuronedioic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020572817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529196A5 (https=
JPWO2020001639A5 (https=
Inventor
ゲン、メイユ
シン、シャンリャン
チャン、チェンチン
ディン、ジャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Shanghai Green Valley Pharmaceutical Co Ltd
Original Assignee
Shanghai Institute of Materia Medica of CAS
Shanghai Green Valley Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS, Shanghai Green Valley Pharmaceutical Co Ltd filed Critical Shanghai Institute of Materia Medica of CAS
Publication of JP2021529196A publication Critical patent/JP2021529196A/ja
Publication of JP2021529196A5 publication Critical patent/JP2021529196A5/ja
Publication of JPWO2020001639A5 publication Critical patent/JPWO2020001639A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020572817A 2018-06-29 2019-06-28 疼痛の治療におけるマンヌロン二酸組成物の使用 Pending JP2021529196A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810714008.2 2018-06-29
CN201810714008.2A CN110652524A (zh) 2018-06-29 2018-06-29 甘露糖醛二酸的组合物在治疗疼痛中的应用
PCT/CN2019/093799 WO2020001639A1 (zh) 2018-06-29 2019-06-28 甘露糖醛二酸的组合物在治疗疼痛中的应用

Publications (3)

Publication Number Publication Date
JP2021529196A true JP2021529196A (ja) 2021-10-28
JP2021529196A5 JP2021529196A5 (https=) 2022-07-04
JPWO2020001639A5 JPWO2020001639A5 (https=) 2022-07-04

Family

ID=68985952

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020572817A Pending JP2021529196A (ja) 2018-06-29 2019-06-28 疼痛の治療におけるマンヌロン二酸組成物の使用

Country Status (7)

Country Link
US (1) US11406653B2 (https=)
EP (1) EP3815695A4 (https=)
JP (1) JP2021529196A (https=)
KR (1) KR20210040941A (https=)
CN (1) CN110652524A (https=)
AU (1) AU2019296850A1 (https=)
WO (1) WO2020001639A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530718A (ja) * 2004-03-24 2007-11-01 中国海洋大学 アルギンオリゴ糖及びその誘導体、並びにそれらの調製と用途
JP2016108474A (ja) * 2014-12-08 2016-06-20 栄治 松村 オリゴ糖の製造方法およびオリゴ糖
CN106344595A (zh) * 2015-07-17 2017-01-25 上海绿谷制药有限公司 褐藻胶寡糖及其衍生物在治疗疼痛中的应用
WO2018011416A1 (de) * 2016-07-14 2018-01-18 HÄUSLER, Lars Pharmazeutische verwendung von beta-d-mannuronsäure
WO2018032272A1 (zh) * 2016-08-15 2018-02-22 上海绿谷制药有限公司 低聚甘露糖醛二酸的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100501584B1 (ko) 2000-02-03 2005-07-18 (주)케이비피 저분자 폴리만유로네이트의 제조방법, 혈청지질개선제로서의 이의 신규 용도 및 이를 함유하는 기능성식품 및 건강 보조 식품
CN106344592A (zh) 2015-07-17 2017-01-25 上海绿谷制药有限公司 还原端1位为羧基的甘露糖醛酸寡糖及其衍生物在治疗帕金森氏症中的应用
CN106344594A (zh) 2015-07-17 2017-01-25 上海绿谷制药有限公司 褐藻胶寡糖及其衍生物在治疗炎症中的应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530718A (ja) * 2004-03-24 2007-11-01 中国海洋大学 アルギンオリゴ糖及びその誘導体、並びにそれらの調製と用途
JP2016108474A (ja) * 2014-12-08 2016-06-20 栄治 松村 オリゴ糖の製造方法およびオリゴ糖
CN106344595A (zh) * 2015-07-17 2017-01-25 上海绿谷制药有限公司 褐藻胶寡糖及其衍生物在治疗疼痛中的应用
WO2018011416A1 (de) * 2016-07-14 2018-01-18 HÄUSLER, Lars Pharmazeutische verwendung von beta-d-mannuronsäure
WO2018032272A1 (zh) * 2016-08-15 2018-02-22 上海绿谷制药有限公司 低聚甘露糖醛二酸的制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MAHDI VOJDANIAN, ET AL.: "The Anti-Migraine Effects of M2000 (β-D-Mannuronic Acid) on a Patient with Rheumatoid Arthritis: Ca", CURRENT CLINICAL PHARMACOLOGY, vol. 12, no. 2, JPN7023002158, 2017, pages 127 - 130, ISSN: 0005077056 *
YING WANG, ET AL.: "Ozonolytic depolymerization of polysaccharides in aqueous solution", CARBOHYDRATE RESEARCH, vol. Vol.319, No.1-4, JPN7023002156, 1999, pages 141 - 147, ISSN: 0005077058 *
ZHAO YANG, ET AL.: "Preparation and characterization of oligomannuronates from alginate degraded by hydrogen peroxide", CARBOHYDRATE POLYMERS, vol. 58, no. 2, JPN7023002157, 2004, pages 115 - 121, ISSN: 0005077057 *

Also Published As

Publication number Publication date
EP3815695A4 (en) 2022-03-02
EP3815695A1 (en) 2021-05-05
WO2020001639A1 (zh) 2020-01-02
CN110652524A (zh) 2020-01-07
US11406653B2 (en) 2022-08-09
KR20210040941A (ko) 2021-04-14
AU2019296850A8 (en) 2021-07-01
AU2019296850A1 (en) 2021-01-28
US20210361684A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
JP6977059B2 (ja) マンヌロン二酸の組成物
CN106344595B (zh) 褐藻胶寡糖及其衍生物在制备治疗疼痛药物中的应用
US11464794B2 (en) Composition of alginic oligosaccharic diacids
JP2021529195A (ja) 炎症の治療におけるマンヌロン二酸組成物の使用
US11406653B2 (en) Use of mannuronic diacid composition in treatment of pain
JP2021528460A (ja) パーキンソン病の治療におけるマンヌロン二酸組成物の使用
JP2021528459A (ja) 糖尿病の治療におけるマンヌロン二酸組成物の使用
HK40016251A (en) Use of a composition of mannuronic diacids in the treatment of pain
US11406651B2 (en) Use of mannuronic diacid composition in treatment of vascular dementia
HK40014917A (en) Use of a composition of oligomeric mannuronic diacid for treating parkinson's disease
HK40014916A (en) Use of a composition of oligomeric mannuronic diacid for treating vascular dementia
HK40014915A (en) Use of a composition of oligomeric mannuronic diacid for treating inflammation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230606

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240105